In the News

January 6, 2020: FemPulse Announces Issuance of Patents in China and Australia

​FemPulse Corporation announced the issuance of two patents from China and Australia covering methods of stimulation of autonomic nerve plexuses in women. Read the Rest of the Article

Read More

Could a doughnut-shaped nerve zapper cure overactive bladders in women?

FemPulse featured in Daily Mail article: Could a doughnut-shaped nerve zapper cure overactive bladders in women?

Read More

July 15, 2019: FemPulse Announces Enrollment of First Patient in Clinical Study for Personalized Treatment of Overactive Bladder (OAB) in Women

FemPulse Corporation announced the first participant has been enrolled in the Company’s clinical trial evaluating physiological responses to therapy delivered with the FemPulse System. Observations from this feasibility study can further help elucidate the mechanisms of action and facilitate tailoring treatment plans for individual patients. Read the Rest of the Article

Read More

Finally, a Wearable Neuromodulation Device for Overactive Bladder

FemPulse featured in MD+DI: Finally, a Wearable Neuromodulation Device for Overactive Bladder 

Read More

​March 26, 2019: FemPulse to Participate in Panel Discussions at the 2019 Bioelectronic Medicine Forum

FemPulse Corporation announced that Donald Deyo, President and CEO, is scheduled to participate in the Entrepreneur Panel I session on bioelectronic medicine in the 2019 Bioelectronic Medicine Forum taking place Thursday, April 4th, in New York City. This is the second annual meeting of the Bioelectronic Medicine Forum, a management and investment conference focused exclusively […]

Read More

​February 25, 2019: FemPulse Announces Enrollment in Multi-Center EVANESCE-OAB Study

FemPulse Corporation announced enrollment of first patients at each of the centers participating in the Company’s EVANESCE-OAB™ (Evaluation of a Non-Implanted Electrical Stimulation Continence Device for Overactive Bladder) U.S. clinical trial. This study will evaluate the treatment of OAB in a home or at-work setting using the Company’s proprietary medical device, the FemPulse System. Read […]

Read More

November 9, 2018: FemPulse Appoints Dr. Robert Kieval as Chief Scientific and Clinical Officer

FemPulse Corporation is pleased to share the appointment of Dr. Robert Kieval as Chief Scientific and Clinical Officer. Dr. Kieval is a medical technology industry veteran, with over 25 years of experience in innovating, financing, and commercializing novel technologies. Dr. Kieval is responsible for continuing to expand the Company’s significant clinical and scientific evidence portfolio. […]

Read More

​May 19, 2018: AUA Clinical Results Presentation Well Attended

The FemPulse clinical results were presented at the American Urology Association (AUA) annual meeting in San Francisco. Dr. Suzette Sutherland, University of Washington, presented that primary objectives regarding fit, comfort and safety were met, as well as positive secondary outcomes regarding patient preference, a reduction in incontinence events and an increase in time between voids.

Read More

April 30, 2018: FemPulse Completes Private Placement Financing

FemPulse Corporation announced completion in the first quarter of 2018 of a private financing round, which will enable acceleration of the development of its novel and proprietary bioelectronic therapy for overactive bladder (OAB) in females. Proceeds will be used for technical and clinical evidence development in preparation for commercialization of the therapy in the US […]

Read More

April 4, 2018: Clinical Results to be Presented at IUGA Annual Meeting

The results of the FemPulse clinical study will be presented at the International Urogynecological Association (IUGA) annual meeting to be held in Vienna, Austria on June 27 – 30, 2018. The invitation provides an opportunity to share the exciting potential of FemPulse with a premier global audience in the field of urogynecology. Dr. Suzette Sutherland, […]

Read More
Arrow Pointing Up
Back to Top